Peter Salzmann Immunovant, Inc. (IMVT) insider trading activity

Peter Salzmann is Chief Executive Officer of Immunovant, Inc.. Currently has a direct ownership of 978,097 shares of IMVT, which is worth approximately $26.9 Million. The most recent transaction as insider was on Nov 20, 2024, when has been sold 16,692 shares (Common Stock) at a price of $25.45 per share, resulting in proceeds of $424,811. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 978K

3.0% 3M change

3.12% 12M change

Total Value Held $26.9 Million

Peter Salzmann Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 20 2024	SELL Open market or private sale	$424,811 $25.45 p/Share	16,692 Reduced 1.68%	978,097 Common Stock
Oct 16 2024	SELL Open market or private sale	$261,845 $28.79 p/Share	9,095 Reduced 0.91%	994,789 Common Stock
Oct 09 2024	SELL Open market or private sale	$131,837 $29.56 p/Share	4,460 Reduced 0.44%	1,003,884 Common Stock
Aug 21 2024	SELL Open market or private sale	$483,381 $32.08 p/Share	15,068 Reduced 1.47%	1,008,344 Common Stock
Jul 17 2024	SELL Open market or private sale	$261,331 $30.09 p/Share	8,685 Reduced 0.84%	1,023,412 Common Stock
Jul 09 2024	SELL Open market or private sale	$129,609 $28.06 p/Share	4,619 Reduced 0.45%	1,032,097 Common Stock
May 22 2024	SELL Open market or private sale	$479,232 $29.65 p/Share	16,163 Reduced 1.54%	1,036,716 Common Stock
Apr 17 2024	SELL Open market or private sale	$1,000,900 $29.37 p/Share	34,079 Reduced 3.14%	1,052,879 Common Stock
Apr 09 2024	SELL Open market or private sale	$149,882 $31.18 p/Share	4,807 Reduced 0.44%	1,086,958 Common Stock
Apr 02 2024	BUY Grant, award, or other acquisition	-	160,534 Added 12.82%	1,091,765 Common Stock
Feb 22 2024	SELL Open market or private sale	$486,362 $36.15 p/Share	13,454 Reduced 1.42%	931,231 Common Stock
Jan 05 2024	SELL Open market or private sale	$147,568 $38.59 p/Share	3,824 Reduced 0.4%	944,685 Common Stock
Nov 22 2023	SELL Open market or private sale	$537,431 $33.14 p/Share	16,217 Reduced 1.68%	948,509 Common Stock
Oct 05 2023	SELL Open market or private sale	$188,446 $35.97 p/Share	5,239 Reduced 0.54%	964,726 Common Stock
Aug 30 2023	SELL Open market or private sale	$1,261,518 $22.22 p/Share	56,774 Reduced 5.53%	969,965 Common Stock
Aug 14 2023	SELL Open market or private sale	$2,235,328 $21.69 p/Share	103,058 Reduced 9.12%	1,026,739 Common Stock
Aug 07 2023	SELL Open market or private sale	$2,202,096 $21.73 p/Share	101,339 Reduced 8.23%	1,129,797 Common Stock
Jul 12 2023	SELL Open market or private sale	$63,787 $19.73 p/Share	3,233 Reduced 0.26%	1,231,136 Common Stock
Apr 18 2023	SELL Open market or private sale	$51,841 $15.27 p/Share	3,395 Reduced 0.27%	1,234,369 Common Stock
Apr 12 2023	BUY Grant, award, or other acquisition	-	243,832 Added 16.46%	1,237,764 Common Stock
Jan 11 2023	SELL Open market or private sale	$67,552 $16.8 p/Share	4,021 Reduced 0.4%	993,932 Common Stock
Oct 13 2022	SELL Open market or private sale	$25,640 $9.18 p/Share	2,793 Reduced 0.28%	997,953 Common Stock
Sep 28 2022	SELL Open market or private sale	$7,495 $4.67 p/Share	1,605 Reduced 0.16%	1,000,746 Common Stock
Aug 30 2022	SELL Open market or private sale	$9,585 $5.83 p/Share	1,644 Reduced 0.16%	1,002,351 Common Stock
Aug 17 2022	BUY Grant, award, or other acquisition	-	451,264 Added 31.01%	1,003,995 Common Stock

Also insider at

CRBP

Corbus Pharmaceuticals Holdings, Inc. Healthcare

Peter Salzmann

Chief Executive Officer

New York, NY

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells IMVT shares.

Notify only if

Value

Insider Trading

Get notified when an Immunovant, Inc. insider buys or sells IMVT shares.

Notify only if

Operation

Value

Type

News

Receive news related to Immunovant, Inc.

Track Activities on IMVT

Account